Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 10/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.44 |
| ▸ | NPC1 | O15118 | 9/20 | 0.44 |
| ▸ | RAB9A | P51151 | 8/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | IKBKB | O14920 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5606406 | 1.00 | CFTR (0.48) | CFTRMEN1KMT2ANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL6294356 | 0.98 | CFTR (0.47) | CFTRMEN1KMT2ANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL6294354 | 0.98 | CFTR (0.47) | CFTRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL5605938 | 0.86 | IKBKB (0.49) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL5605941 | 0.86 | IKBKB (0.49) | MEN1KMT2ANPC1RAB9AMAPT | |
| Hydrochloric Acid SCHEMBL6294375 | 0.84 | IKBKB (0.48) | MEN1KMT2ANPC1RAB9AMAPT | |
| Hydrochloric Acid SCHEMBL6294377 | 0.84 | IKBKB (0.48) | MEN1KMT2ANPC1RAB9AMAPT | |
| Hydrochloric Acid SCHEMBL6294376 | 0.84 | IKBKB (0.48) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL5158286 | 0.81 | HTR1A (0.49) | CFTRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL5158294 | 0.81 | HTR1A (0.49) | CFTRMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007026219-A2 | COMBINATIONS OF A 5-HT1B ANTAGONIST WITH A NORADRENALIN RE-UPTAKE INHIBITOR OR A SEROTONIN NORADRENALIN REUTAKE INHIBITOR FOR TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2007-03-08 | — | — | WO | claimed |
| EP-0929528-B1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER (US) | 2003-07-23 | — | — | EP | claimed |
| US-20020147194-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. | 2002-10-10 | — | — | US | claimed |
| US-20020091117-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. | 2002-07-11 | — | — | US | claimed |
| US-20020091118-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. | 2002-07-11 | — | — | US | claimed |
| US-20020091119-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. | 2002-07-11 | — | — | US | claimed |
| US-20020072519-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. | 2002-06-13 | — | — | US | claimed |
| US-6403592-B1 | SEROTONIN REUPTAKE INHIBITORS | PFIZER INC | 2002-06-11 | — | — | US | claimed |
| US-20020049211-A1 | Combination treatment for depression and anxiety | SOBOLOV-JAYNES SUSAN BETH (US) | 2002-04-25 | — | — | US | claimed |
| US-20020049214-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER PRODUCTS INC. | 2002-04-25 | — | — | US | claimed |
| EP-1186318-A2 | Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | claimed |
| WO-2007026219-A2 | COMBINATIONS OF A 5-HT1B ANTAGONIST WITH A NORADRENALIN RE-UPTAKE INHIBITOR OR A SEROTONIN NORADRENALIN REUTAKE INHIBITOR FOR TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| EP-1592772-A2 | 5HT7 ANTAGONISTS AND INVERSE AGONISTS | Pfizer Products Incorporated (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6921760-B2 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. (US) | 2005-07-26 | — | — | US | disclosed |
| WO-2005053701-A1 | COMBINATION OF DOPAMINE AGONISTS AND ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER PRODUCTS INC. (US) | 2005-06-16 | — | — | WO | disclosed |
| US-6380186-B1 | PSYCHOTHERAPEUTIC AGENTS | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| US-20020049211-A1 | Combination treatment for depression and anxiety | SOBOLOV-JAYNES SUSAN BETH (US) | 2002-04-25 | — | — | US | disclosed |
| EP-1186318-A2 | Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| EP-0929528-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998014433-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. (US) | 1998-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091118-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | MRPL21, ARAF, ARL1 | CFTR 4086/4885MEN1 863/4885KMT2A 1683/4885 |
| US-20020091119-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | CFTR 4086/4885MEN1 863/4885KMT2A 1683/4885 |
| US-20020147194-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | CFTR 4086/4885MEN1 863/4885KMT2A 1683/4885 |
| US-20020049214-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | CFTR 3991/4885MEN1 698/4885KMT2A 1959/4885 |
| US-20020049211-A1 | Combination treatment for depression and anxiety | HTR1A, HTR1D, HTR5A | CFTR 2820/4885MEN1 1555/4885KMT2A 913/4885 |
| US-20020072519-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | CFTR 4086/4885MEN1 863/4885KMT2A 1683/4885 |
| US-20020091117-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | MRPL21, ARAF, ARL1 | CFTR 4086/4885MEN1 863/4885KMT2A 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.